---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-22-019267"
form_type: "8-K"
ticker: "ARWR"
cik: "0000879407"
company_name: "ARROWHEAD PHARMACEUTICALS, INC."
filed_at: "2022-05-10T23:59:59+00:00"
generated_at: "2026-06-25T22:08:05.520383+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Arrowhead Q2 FY2022 net income $44.4M on revenue $151.8M vs prior year loss

## Summary
- Revenue $151.8M for Q2 ended Mar 31, 2022, up from $32.8M YoY; net income $44.4M ($0.41 diluted EPS) vs net loss $26.8M ($0.26 loss) year ago.
- Initiated PALISADE Phase 3 study of ARO-APOC3 in familial chylomicronemia syndrome; completed enrollment of 204 patients in Phase 2b ARCHES-2 for ARO-ANG3.
- Formed Visirna Therapeutics joint venture with Vivo Capital to expand into Greater China.
- Broke ground on new manufacturing facility; awarded up to $18.5M in tax incentives from Wisconsin and Verona.
- Total cash and investments of $603.5M as of March 31, 2022.

## SEC filing metadata
- accession: 0001564590-22-019267
- form_type: 8-K
- ticker: ARWR
- cik: 0000879407
- company_name: ARROWHEAD PHARMACEUTICALS, INC.
- filed_at: 2022-05-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/879407/000156459022019267/0001564590-22-019267-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/879407/000156459022019267/arwr-8k_20220510.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-22-019267
- JSON: https://secwatch.observer/filing/0001564590-22-019267.json
- Plain text: https://secwatch.observer/filing/0001564590-22-019267.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.